Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

David A. Frank, MD, PhD


Medical Oncology

Make an Appointment

Physician

  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Leukemias

Contact Information

  • Appointments617-632-6140
  • Office Phone Number617-632-4714
  • Fax617-394-2782

Bio

Dr. Frank received his MD in 1986 and PhD in 1987 from Yale University. After serving as an intern, resident, and chief resident in internal medicine at Yale, he completed training in medical oncology at Dana-Farber Cancer Institute, followed by a postdoctoral fellowship in intracellular signal transduction at Harvard Medical School. In 1995, Dr. Frank brought his laboratory group back to Dana-Farber, where he also maintains a clinical practice.

Board Certification:

  • Internal Medicine, 1989
  • Medical Oncology, 1993

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology
  • Harvard Medical School, Signal Transduction

Residency:

  • Yale University School of Medicine, Internal Medicine

Medical School:

  • Yale University School of Medicine

Recent Awards:

  • Teaching Award, Class of 2002, Harvard Medical School 1999
  • Discovery Program Award 2001
  • Kittredge Research Award 2002
  • Biological and Biomedical Sciences Teaching Award, Harvard Medical School 2003
  • Hoopes Prize-Mentor, Harvard University 2003
  • Collaborative Physician Practice Award 2008
  • Fellow, Molecular Medicine Society 1999
  • Fellow, American College of Physicians 2002
  • Award for Outstanding Research Achievement, Nature Biotechnology SciCafe 2009
  • Partners in Excellence Award, Partners HealthCare 2009
  • Team Impact Award, Dana-Farber Cancer Institute 2009

Research

Targeting Signaling Pathways for Cancer Therapy

Our laboratory focuses on the intracellular signaling pathways that control normal cellular function and become subverted in the development of cancer. The ultimate goal is to use this knowledge to design targeted molecular inhibitors for the treatment of cancer.Much of our work is centered on a family of cellular regulators called STATs, or signal transducers and activators of transcription. Once activated, STATs induce the expression of specific target genes that control critical cellular processes. In many kinds of cancer, we have found that STATs are activated inappropriately, thereby driving growth and survival in a cell that would otherwise remain quiescent or die. Thus, understanding how STATs function is a crucial step in understanding cancer biology.In this context, our laboratory has focused on understanding the role that STATs play in the development and treatment of cancers. We are dissecting the specific genes that are targeted by STATs and are necessary for mediating their biological effects. We are also analyzing how STAT function is modulated by other regulators of chromatin structure such as histones and DNA methylation.In addition, we are developing inhibitors of STAT function as a therapy for cancer. Whereas malignant cells are extremely sensitive to inhibition of STAT signaling, normal cells are able to tolerate STAT inhibition with minimal consequences. Thus, STAT inhibitors are particularly attractive anticancer drugs. We are approaching this area in three ways. First, we have found that some anti-cancer and chemopreventive agents are potent inhibitors of STAT signaling. We are now trying to extend and enhance these findings to harness the clinical potential of these drugs. Second, we have designed systems to rapidly screen thousands of compounds for activity as STAT inhibitors, testing a number of chemical "libraries" which are likely to contain active molecules. Finally, in conjunction with synthetic chemists, we have designed unique small molecules to act as specific STAT inhibitors. These compounds are being tested in cellular and animal systems to assess their activity, and we are beginning clinical trials of this therapeutic strategy in cancer patients.We feel confident that this type of rational development of signal transduction inhibitors will provide the next generation of highly active and less toxic cancer therapies.

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML. Blood. 2021 Jun 17; 137(24):3403-3415.
View in: PubMed

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 Jun 04.
View in: PubMed

Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer. Mol Cancer Res. 2021 Apr 30.
View in: PubMed

Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles. Mol Cancer Ther. 2021 04; 20(4):726-738.
View in: PubMed

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98.
View in: PubMed

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1).
View in: PubMed

Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability. bioRxiv. 2020 Oct 28.
View in: PubMed

Retraction Note: Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature. 2020 07; 583(7814):154.
View in: PubMed

Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors. Bioorg Med Chem. 2020 06 15; 28(12):115542.
View in: PubMed

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
View in: PubMed

CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3. Neoplasia. 2020 01; 22(1):47-59.
View in: PubMed

Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3? Cancer Cell. 2019 11 11; 36(5):459-461.
View in: PubMed

Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature. 2019 09; 573(7772):139-143.
View in: PubMed

Cancer Biomarkers for Integrative Oncology. Curr Oncol Rep. 2019 03 05; 21(4):32.
View in: PubMed

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts. Oncogenesis. 2019 Feb 22; 8(3):15.
View in: PubMed

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018 12 11; 2(23):3428-3442.
View in: PubMed

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 12 03; 128(12):5479-5488.
View in: PubMed

Phagocytes from Mice Lacking the Sts Phosphatases Have an Enhanced Antifungal Response to Candida albicans. mBio. 2018 07 17; 9(4).
View in: PubMed

IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res. 2018 09 01; 78(17):4957-4970.
View in: PubMed

The STAT3 Target Gene TNFRSF1A Modulates the NF-?B Pathway in Breast Cancer Cells. Neoplasia. 2018 05; 20(5):489-498.
View in: PubMed

Rare mutations provide unique insight into oncogenic potential of STAT transcription factors. J Clin Invest. 2018 01 02; 128(1):113-115.
View in: PubMed

Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. Trends Cancer. 2017 12; 3(12):816-827.
View in: PubMed

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report. J Natl Cancer Inst Monogr. 2017 11 01; 2017(52).
View in: PubMed

The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol Immunother. 2018 01; 67(1):13-23.
View in: PubMed

"I Was Not Sick and I Didn't Need to Recover": Methadone Maintenance Treatment (MMT) as a Refuge from Criminalization. Subst Use Misuse. 2018 01 28; 53(2):311-322.
View in: PubMed

Marrying Step Feed with Secondary Clarifier Improvements to Significantly Increase Peak Wet Weather Treatment Capacity: An Integrated Methodology. Water Environ Res. 2017 Aug 01; 89(8):724-731.
View in: PubMed

NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2016; 2:16030.
View in: PubMed

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 10 06; 128(14):1845-1853.
View in: PubMed

Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget. 2016 08 09; 7(32):51651-51664.
View in: PubMed

Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. Oncotarget. 2016 Jul 19; 7(29):46301-46314.
View in: PubMed

Characterizing shallow secondary clarifier performance where conventional flux theory over-estimates allowable solids loading rate. Water Sci Technol. 2016; 74(2):324-32.
View in: PubMed

STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy. ChemMedChem. 2016 Apr 19; 11(8):795-801.
View in: PubMed

Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3. Cancer Cytopathol. 2015 Dec; 123(12):696-706.
View in: PubMed

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch? Oncoscience. 2015; 2(11):912.
View in: PubMed

Fistulizing Epstein-Barr virus-positive plasmablastic lymphoma in an HIV-positive man. Br J Dermatol. 2016 Feb; 174(2):398-401.
View in: PubMed

Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem. 2015 Aug 27; 58(16):6589-606.
View in: PubMed

Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways. J Biol Chem. 2015 Sep 25; 290(39):23553-62.
View in: PubMed

Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. Mol Cell Biol. 2015 Oct; 35(19):3284-300.
View in: PubMed

Mass-spectrometry-based molecular characterization of extracellular vesicles: lipidomics and proteomics. J Proteome Res. 2015 Jun 05; 14(6):2367-84.
View in: PubMed

Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer. Genes Cancer. 2015 Mar; 6(3-4):153-68.
View in: PubMed

Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J Immunol. 2015 Apr 01; 194(7):3180-90.
View in: PubMed

ACP Journal Club. Review: Self-collected samples are less accurate for HPV testing than clinician-collected samples. Ann Intern Med. 2014 Aug 19; 161(4):JC11.
View in: PubMed

High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy. 2015 Jan; 26(1):84-91.
View in: PubMed

STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b. Cancers (Basel). 2014 Apr 23; 6(2):958-68.
View in: PubMed

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 2015 Feb 26; 34(9):1073-82.
View in: PubMed

Fold change of nuclear NF-?B determines TNF-induced transcription in single cells. Mol Cell. 2014 Mar 20; 53(6):867-79.
View in: PubMed

STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-?B to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. 2014 Jan 28; 7(310):ra11.
View in: PubMed

Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. . 2014 May; 13(5):1194-205.
View in: PubMed

ACP Journal Club. Review: low-dose CT screening reduces lung cancer and mortality in current or former smokers. Ann Intern Med. 2013 Nov 19; 159(10):JC3.
View in: PubMed

Transcription factor STAT3 as a prognostic marker and therapeutic target in cancer. J Clin Oncol. 2013 Dec 20; 31(36):4560-1.
View in: PubMed

Targeting transcription factors: promising new strategies for cancer therapy. Curr Opin Oncol. 2013 Nov; 25(6):652-8.
View in: PubMed

A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury. J Am Soc Nephrol. 2014 Jan; 25(1):105-18.
View in: PubMed

Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br J Haematol. 2013 Oct; 163(2):182-93.
View in: PubMed

STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol. 2013 Aug; 33(15):2879-90.
View in: PubMed

JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition. JAKSTAT. 2013 Oct 01; 2(4):e24635.
View in: PubMed

Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol. 2014 Jan 25; 382(1):616-621.
View in: PubMed

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013 Feb; 45(2):131-2.
View in: PubMed

Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets. JAKSTAT. 2012 Oct 01; 1(4):292-9.
View in: PubMed

Targeting STATs for cancer therapy: "Undruggable" no more. JAKSTAT. 2012 Oct 01; 1(4):261-2.
View in: PubMed

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
View in: PubMed

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
View in: PubMed

STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT. 2012 Apr 01; 1(2):55-64.
View in: PubMed

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. Leukemia. 2012 Jun; 26(6):1407-10.
View in: PubMed

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351.
View in: PubMed

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet. 2011 Nov 01; 20(21):4143-54.
View in: PubMed

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. . 2011 Jul 01; 12(1):9-46.
View in: PubMed

The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35.
View in: PubMed

A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget. 2011 Jun; 2(6):518-24.
View in: PubMed

STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011 Mar 15; 17(6):1452-62.
View in: PubMed

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12):3421-9.
View in: PubMed

STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents. Mol Cell Pharmacol. 2011 Jan 01; 3(1):13-19.
View in: PubMed

Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010 Dec; 24(12):2100-9.
View in: PubMed

Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 2010 Nov; 78(5):903-8.
View in: PubMed

Determination of alternate splicing events using the Affymetrix Exon 1.0 ST arrays. Methods Mol Biol. 2010; 632:63-72.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin Pharmacol Ther. 2009 Oct; 86(4):365-7.
View in: PubMed

STAT6 in PMBL: pathogenic or passenger? Blood. 2009 Aug 06; 114(6):1133-4.
View in: PubMed

Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009 Jun; 7(6):966-76.
View in: PubMed

CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009 Apr 15; 15(8):2583-7.
View in: PubMed

A SnoN-Ccd1 pathway promotes axonal morphogenesis in the mammalian brain. J Neurosci. 2009 Apr 01; 29(13):4312-21.
View in: PubMed

Evaluation of novel synthetic conditioning polymers for shampoos. J Cosmet Sci. 2009 Mar-Apr; 60(2):239-50.
View in: PubMed

Targeting transcription factors for cancer therapy. IDrugs. 2009 Jan; 12(1):29-33.
View in: PubMed

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15; 112(13):5095-102.
View in: PubMed

Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci. 2008 Jun 04; 28(23):5870-8.
View in: PubMed

STAT1 expression is not required for polyp formation in Min mice. Mol Carcinog. 2008 Feb; 47(2):75-9.
View in: PubMed

Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer. ACP J Club. 2008 Jan-Feb; 148(1):7.
View in: PubMed

A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis. Transl Oncogenomics. 2007; 2:99-105.
View in: PubMed

Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007 Oct 01; 13(19):5665-9.
View in: PubMed

A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells. Cancer Res. 2007 Feb 01; 67(3):1254-61.
View in: PubMed

STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007 Jun 28; 251(2):199-210.
View in: PubMed

Monocyte 15-lipoxygenase expression is regulated by a novel cytosolic signaling complex with protein kinase C delta and tyrosine-phosphorylated Stat3. J Immunol. 2006 Sep 15; 177(6):3771-81.
View in: PubMed

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst. 2006 Sep 06; 98(17):1238-47.
View in: PubMed

TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. Hum Mol Genet. 2006 Sep 15; 15(18):2709-20.
View in: PubMed

Identification of human STAT5-dependent gene regulatory elements based on interspecies homology. J Biol Chem. 2006 Sep 08; 281(36):26216-24.
View in: PubMed

STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene. 2007 Jan 11; 26(2):224-33.
View in: PubMed

Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol. 2006 Jun; 126(6):1396-402.
View in: PubMed

Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry. 2006 May 02; 45(17):5599-605.
View in: PubMed

IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006 Sep 01; 108(5):1571-9.
View in: PubMed

Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 2006 Apr 01; 66(7):3649-57.
View in: PubMed

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006 Mar 15; 66(6):3162-8.
View in: PubMed

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005 Dec; 42(6):1329-38.
View in: PubMed

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
View in: PubMed

Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005 Jun 15; 65(12):5054-62.
View in: PubMed

A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leuk Res. 2005 Sep; 29(9):1009-18.
View in: PubMed

The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. 2005 Jul 15; 106(2):690-7.
View in: PubMed

Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A. 2005 Jan 04; 102(1):175-9.
View in: PubMed

Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. . 2004 Nov; 3(11):1045-50.
View in: PubMed

Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem. 2004 Dec 24; 279(52):54724-30.
View in: PubMed

Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. Biochim Biophys Acta. 2004 Sep 17; 1679(3):230-47.
View in: PubMed

IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. Carcinogenesis. 2004 Nov; 25(11):2247-55.
View in: PubMed

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res. 2004 Feb; 28(2):139-47.
View in: PubMed

Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis. Leuk Res. 2003 Sep; 27(9):859-63.
View in: PubMed

STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood. 2003 Oct 15; 102(8):3016-24.
View in: PubMed

Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003 Sep 12; 278(37):35501-7.
View in: PubMed

In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun; 9(6):2166-72.
View in: PubMed

Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3. Mol Cell Biol. 2003 Jun; 23(11):3918-28.
View in: PubMed

StAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat Res. 2003; 115:267-91.
View in: PubMed

The role of STATs in apoptosis. Curr Mol Med. 2002 Jun; 2(4):381-92.
View in: PubMed

Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA. 2001 Nov 28; 286(20):2554-9.
View in: PubMed

The ribosomal S6 kinases, cAMP-responsive element-binding, and STAT3 proteins are regulated by different leukemia inhibitory factor signaling pathways in mouse embryonic stem cells. J Biol Chem. 2001 Dec 07; 276(49):46204-11.
View in: PubMed

CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol. 2001 Oct; 19(4):791-8.
View in: PubMed

The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol. 2001 Aug; 159(2):483-91.
View in: PubMed

A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. Blood. 2001 Apr 15; 97(8):2230-7.
View in: PubMed

A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001 Feb; 27(2):172-80.
View in: PubMed

CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. Exp Hematol. 2001 Feb; 29(2):209-20.
View in: PubMed

[Local tumor control and cosmetic outcome following breast-conserving surgery and radiation up to a total dose of 56 Gy without boost in breast cancer]. Strahlenther Onkol. 2001 Jan; 177(1):25-32.
View in: PubMed

Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000 Dec; 157(6):1937-45.
View in: PubMed

The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis. 2000 Dec; 10(3):271-5.
View in: PubMed

SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood. 2000 Nov 15; 96(10):3422-30.
View in: PubMed

Ras-mediated FGF signaling is required for the formation of posterior but not anterior neural tissue in Xenopus laevis. Dev Biol. 2000 Nov 01; 227(1):183-96.
View in: PubMed

Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections. J Immunol. 2000 Oct 01; 165(7):4120-6.
View in: PubMed

STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. Cell Immunol. 2000 Jun 15; 202(2):124-35.
View in: PubMed

Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000 May 15; 95(10):3183-90.
View in: PubMed

STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000 May 15; 19(21):2496-504.
View in: PubMed

TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol. 2000 May; 28(5):584-93.
View in: PubMed

STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000 Mar 15; 95(6):2118-25.
View in: PubMed

[The JAK-STAT signaling pathway and its role in oncogenesis, immunomodulation and development]. Med Clin (Barc). 2000 Feb 19; 114(6):227-34.
View in: PubMed

A novel pleckstrin homology-related gene family defined by Ipl/Tssc3, TDAG51, and Tih1: tissue-specific expression, chromosomal location, and parental imprinting. Mamm Genome. 1999 Dec; 10(12):1150-9.
View in: PubMed

Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol. 1999 Nov; 19(11):7519-28.
View in: PubMed

Level of in utero cocaine exposure and neonatal ultrasound findings. Pediatrics. 1999 Nov; 104(5 Pt 1):1101-5.
View in: PubMed

STAT signaling in the pathogenesis and treatment of cancer. Mol Med. 1999 Jul; 5(7):432-56.
View in: PubMed

Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 1999 Jun 15; 93(12):4354-64.
View in: PubMed

HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. Virology. 1999 May 10; 257(2):314-21.
View in: PubMed

The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol. 1999 Apr 15; 162(8):4472-81.
View in: PubMed

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999 Apr; 5(4):444-7.
View in: PubMed

IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol. 1999 Jan 01; 162(1):299-304.
View in: PubMed

A single gene for human TRAF-3 at chromosome 14q32.3 encodes a variety of mRNA species by alternative polyadenylation, mRNA splicing and transcription initiation. Mol Immunol. 1998 Dec; 35(18):1189-206.
View in: PubMed

Blood pressure in children exposed prenatally to cocaine. Clin Pediatr (Phila). 1998 Nov; 37(11):659-64.
View in: PubMed

Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998 Aug 01; 102(3):561-75.
View in: PubMed

Neonatal neurobehavioral and neuroanatomic correlates of prenatal cocaine exposure. Problems of dose and confounding. Ann N Y Acad Sci. 1998 Jun 21; 846:40-50.
View in: PubMed

IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet. 1998 Apr; 7(4):597-608.
View in: PubMed

Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood. 1998 Feb 15; 91(4):1341-54.
View in: PubMed

B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997 Dec 15; 100(12):3140-8.
View in: PubMed

Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol. 1997 Nov 01; 159(9):4350-5.
View in: PubMed

The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum Mol Genet. 1997 Nov; 6(12):2021-9.
View in: PubMed

Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science. 1997 Oct 17; 278(5337):477-83.
View in: PubMed

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 1997 Oct 01; 57(19):4177-82.
View in: PubMed

Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med. 1997 Mar 17; 185(6):1035-42.
View in: PubMed

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997 Feb 04; 94(3):861-6.
View in: PubMed

BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 1996 Nov; 10(11):1724-30.
View in: PubMed

Delayed tyrosine phosphorylation and nuclear expression of STAT1 following antigen receptor stimulation of B lymphocytes. J Immunol. 1996 Sep 15; 157(6):2299-309.
View in: PubMed

Antigen-receptor engagement in B cells induces nuclear expression of STAT5 and STAT6 proteins that bind and transactivate an IFN-gamma activation site. J Immunol. 1996 Jul 01; 157(1):39-47.
View in: PubMed

Late dose-response effects of prenatal cocaine exposure on newborn neurobehavioral performance. Pediatrics. 1996 Jul; 98(1):76-83.
View in: PubMed

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996 Mar 01; 183(3):811-20.
View in: PubMed

Signal transduction pathways activated by ciliary neurotrophic factor and related cytokines. Perspect Dev Neurobiol. 1996; 4(1):3-18.
View in: PubMed

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med. 1995 Dec 01; 182(6):1801-6.
View in: PubMed

Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci U S A. 1995 Sep 12; 92(19):8665-9.
View in: PubMed

Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A. 1995 Aug 15; 92(17):7779-83.
View in: PubMed

The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
View in: PubMed

Assessing unmet need for services for pediatric undernutrition. HSPH MPH Student Research Team. Am J Prev Med. 1995 May-Jun; 11(3 Suppl):39-44.
View in: PubMed

The PKD1 gene produces a developmentally regulated protein in mesenchyme and vasculature. Nat Med. 1995 Apr; 1(4):359-64.
View in: PubMed

Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood. 1995 Mar 01; 85(5):1396-403.
View in: PubMed

CREB: a mediator of long-term memory from mollusks to mammals. Cell. 1994 Oct 07; 79(1):5-8.
View in: PubMed

Sp1 elements protect a CpG island from de novo methylation. Nature. 1994 Sep 29; 371(6496):435-8.
View in: PubMed

Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus. Science. 1993 Dec 03; 262(5139):1575-9.
View in: PubMed

Children exposed to cocaine prenatally: pieces of the puzzle. Neurotoxicol Teratol. 1993 Sep-Oct; 15(5):298-300; discussion 311-2.
View in: PubMed

Synthetic lethal mutations suggest interactions between U5 small nuclear RNA and four proteins required for the second step of splicing. Mol Cell Biol. 1992 Nov; 12(11):5197-205.
View in: PubMed

Cocaine and marijuana use during pregnancy by women intending and not intending to breast-feed. J Am Diet Assoc. 1992 Feb; 92(2):215-7.
View in: PubMed

Neonatal body proportionality and body composition after in utero exposure to cocaine and marijuana. J Pediatr. 1990 Oct; 117(4):622-6.
View in: PubMed

Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med. 1989 Mar 23; 320(12):762-8.
View in: PubMed

Biochemical characterization of tyrosine kinase and phosphotyrosine phosphatase activities of HL-60 leukemia cells. Cancer Res. 1988 Aug 01; 48(15):4299-306.
View in: PubMed

Measurement of large or irregular-shaped septal perforations by computed tomography. Radiol Technol. 1988 May-Jun; 59(5):409-12.
View in: PubMed

Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells. Cancer Res. 1988 Jan 01; 48(1):52-8.
View in: PubMed

Commercial discharge packs and breast-feeding counseling: effects on infant-feeding practices in a randomized trial. Pediatrics. 1987 Dec; 80(6):845-54.
View in: PubMed

Regulation of protein phosphotyrosine content by changes in tyrosine kinase and protein phosphotyrosine phosphatase activities during induced granulocytic and monocytic differentiation of HL-60 leukemia cells. Biochem Biophys Res Commun. 1986 Oct 15; 140(1):440-7.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 522B
Boston, MA 02215
Get Directions

Ratings

Top